kabutan

SANTEN PHARMA, First Half Net Income Decreases by 26%

Thu Nov 6, 2025 3:30 pm JST Earnings

4536 SANTEN PHARMACEUTICAL CO.,LTD. 【IFRS】

Earnings Report

SANTEN PHARMACEUTICAL CO.,LTD. <4536> [TSE Prime] announced its financial results (based on IFRS) after the market closed on November 6th (15:30). The consolidated net income for the cumulative second quarter of the fiscal year ending March 2026 (April to September) decreased 25.7% from the same period last year to 13.9 billion yen. Progress toward the full-year plan of 34.0 billion yen was 41.0%, also falling below the five-year average of 81.3%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the October to March period (second half) is expected to grow 14.7% from the same period last year, reaching 20.0 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated net income amounted to 8.06 billion yen, a 0.9% decrease compared to the same period last year. The operating profit margin remained almost flat, changing from 15.0% in the same period last year to 15.0%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 145,806 25,099 24,075 19,280 52.1 80.6 Nov 7, 2023 IFRS
Apr - Sep, 2024 146,404 23,873 23,839 18,772 52.9 50.2 Nov 7, 2024 IFRS
Apr - Sep, 2025 137,879 17,915 17,634 13,940 41.8 ー Nov 6, 2025 IFRS
YoY -5.8% -25.0% -26.0% -25.7% -21.0%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 19 May 13, 2025 IFRS
Apr - Sep, 2025 Results 137,879 17,915 17,634 13,940 41.8 19 Nov 6, 2025 IFRS
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 153,600 23,007 23,642 17,484 50.1 19 May 13, 2025 IFRS
Oct - Mar, 2025 Guidance 156,121 26,085 ー 20,060 62.4 19 Nov 6, 2025 IFRS
YoY +1.6% +13.4% － +14.7% +24.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 301,965 38,541 29,874 26,642 72.6 33 May 9, 2024 IFRS
Mar, 2025 300,004 46,880 47,481 36,256 104.0 36 May 13, 2025 IFRS
Mar, 2026 Guidance 294,000 44,000 ー 34,000 105.7 38 Aug 7, 2025 IFRS
YoY -2.0% -6.1% － -6.2% +1.7%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 71,633 10,718 10,389 8,139 22.9 15.0 Nov 7, 2024 IFRS
Oct - Dec, 2024 76,369 11,322 11,470 8,693 24.8 14.8 Feb 6, 2025 IFRS
Jan - Mar, 2025 77,231 11,685 12,172 8,791 25.2 15.1 May 13, 2025 IFRS
Apr - Jun, 2025 68,737 7,573 7,450 5,878 17.3 11.0 Aug 7, 2025 IFRS
Jul - Sep, 2025 69,142 10,342 10,184 8,062 24.2 15.0 Nov 6, 2025 IFRS
YoY -3.5% -3.5% -2.0% -0.9% +5.3%

Related Articles